Inclusion Criteria:

          -  Has histologically confirmed diagnosis of RCC with clear cell component

          -  Has received no prior systemic therapy for advanced ccRCC

          -  Male participants are abstinent from heterosexual intercourse or agree to use
             contraception during and for at least 7 days after last dose of study intervention
             with belzutifan and lenvatinib

          -  Female participants are not pregnant or breastfeeding and are either not a woman of
             child-bearing potential (WOCBP) or use a contraceptive method that is highly effective
             or are abstinent from heterosexual intercourse during the intervention period and for
             at least 120 days after pembrolizumab or pembrolizumab/quavonlimab or for at least 30
             days after last dose of lenvatinib or belzutifan, whichever occurs last

          -  Has adequately controlled blood pressure with or without antihypertensive medications

          -  Has adequate organ function

          -  Participants receiving bone resorptive therapy must have therapy initiated at least 2
             weeks prior to randomization/allocation

        Exclusion Criteria:

          -  Has a known additional malignancy that is progressing or has required active treatment
             within the past 3 years

          -  Has had major surgery, other than nephrectomy within 4 weeks prior to randomization

          -  Has known central nervous system (CNS) metastases and/or carcinomatous meningitis

          -  Has received prior radiotherapy within 2 weeks prior to first dose of study
             intervention

          -  Has hypoxia or requires intermittent supplemental oxygen or requires chronic
             supplemental oxygen

          -  Has clinically significant cardiac disease within 12 months from first dose of study
             intervention

          -  Has a history of interstitial lung disease

          -  Has symptomatic pleural effusion; a participant who is clinically stable following
             treatment of this condition is eligible

          -  Has preexisting gastrointestinal or non-gastrointestinal fistula

          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
             or any other form of immunosuppressive therapy within 7 days prior to the first dose
             of study treatment

          -  Has a known psychiatric or substance abuse disorder that would interfere with
             requirements of the study

          -  Has received a live or live-attenuated vaccine within 30 days before the first dose of
             study drug; killed vaccines are allowed

          -  Has an active autoimmune disease that has required systemic treatment in the past 2
             years

          -  Has a history of noninfectious pneumonitis that required steroids or has current
             pneumonitis

          -  Has an active infection requiring systemic therapy

          -  Has a known history of human immunodeficiency virus (HIV) infection

          -  Has a known history of Hepatitis B

          -  Has radiographic evidence of intratumoral cavitation, encasement or invasion of a
             major blood vessel

          -  Has clinically significant history of bleeding within 3 months prior to randomization

          -  Has had an allogenic tissue/solid organ transplant